Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Refractory Mantle Cell Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Diffuse Large B Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Non Hodgkin Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then for up to 5 years.
OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then for up to 5 years.
Tracking Information
- NCT #
- NCT04205409
- Collaborators
- National Cancer Institute (NCI)
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Andrew Cowan Fred Hutch/University of Washington Cancer Consortium
Get Well Soon